Use of Ceftazidime-Avibactam in Infants and Children

Marcia L. Buck, PharmD, FCCP, FPPAG, BCPPS


Pediatr Pharm. 2019;25(5) 

In This Article


Ceftazidime-avibactam provides a new option for the treatment of infections caused by most beta-lactamase and carbapenemase-producing Gram negative bacteria. In clinical trials, it has been shown to be safe and effective in patients as young as 3 months of age with complicated intra-abdominal or urinary tract infections. While its benefits are clear, recent reports of the development of ceftazidime-avibactam resistance highlight the need for continued efforts to restrict its use to treatment of organisms known to be resistant to standard therapies.